NCT02270567
RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide
Enrolling by Invitation
Not specifiedAges 18+ObservationalWren Laboratories LLC
~400 participants
Updated 2025-11-13 on ClinicalTrials.gov
What's tested:NETest
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Tumor-related recurrence or progression
Measured over 5 years
+2 more outcomes measured
Conditions
NCT02270567
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Wren Laboratories
Branford, Connecticutno site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Gastroenteropancreatic neuroendocrine tumor
Bronchopulmonary neuroendocrine tumor
Gastroenteropancreatic neuroendocrine carcinoma
Pre- and post-surgical patients
Watch \& Wait/no treatment
Treatment including somatostatin analogues, PRRT, targeted therapies.
Patient provides informed consent
Exclusion
N/A
What this trial measures
- Tumor-related recurrence or progression5 years
Image-based identification of recurrent or progressive tumor disease
- Tumor-related diagnosis1 year
Histological confirmation of neuroendocrine tumor
- Tumor-related mortality10 years
Survival from disease